Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge

Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge

Abstract Studies conducted prior to SARS-CoV-2 Omicron demonstrated that sotrovimab and remdesivir reduced hospitalization among high-risk outpatients with mild to moderate COVID-19. However, their effectiveness has not been directly compared. This study examined all high-risk outpatients with mild...

Full description

Bibliographic Details
Main Authors: Supavit Chesdachai, Christina G. Rivera, Kristin C. Cole, Hilary R. Teaford, Maria L. Gonzalez Suarez, Jennifer J. Larsen, Ravindra Ganesh, Sidna Tulledge-Scheitel, Raymund R. Razonable
Format: Article
Language:English
Published: Nature Portfolio 2024-03-01
Series:Scientific Reports
Subjects:
COVID-19
Outcome
Remdesivir
SARS-2-CoV
Sotrovimab
Online Access:https://doi.org/10.1038/s41598-024-56195-y

Internet

https://doi.org/10.1038/s41598-024-56195-y

Similar Items